A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both (SURPASS-PEDS)

NCT05260021 PHASE3 COMPLETED Results posted

The purpose of this study is to learn more about the safety and efficacy of tirzepatide compared to placebo in children or teenagers with type 2 diabetes taking metformin, or basal insulin, or both. The overall study will last about 60 weeks with up to 14 clinic visits and 6 phone visits. Clinic visits will include blood sample collection, physical exam and questionnaire.

Details

Lead sponsor	Eli Lilly and Company
Phase	PHASE3
Status	COMPLETED
Enrolment	99
Start date	Wed Apr 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Type2 Diabetes
• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• T2D
• T2DM (Type 2 Diabetes Mellitus)
• Glucose Metabolism Disorders
• Endocrine System Diseases
• Metabolic Disease

Interventions

• Tirzepatide Dose 1
• Tirzepatide Dose 2
• Placebo

Countries

France, Italy, United Kingdom, Israel, Mexico, Australia, United States, Brazil, India